.Pharmacolibrary.Drugs.ATC.J.J06BB04 .Pharmacolibrary.Drugs.ATC.J.J06BB04| name: | HepatitisBImmunoglobulin | |
| ATC code: | J06BB04 | |
| route: | intramuscular | |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 7 | L |
| clearance: | 0.18 | L/h |
| other parameters in model implementation | ||
Hepatitis B immunoglobulin (HBIG) is a human immune globulin containing a high titer of antibodies against hepatitis B virus (HBV). It is used for post-exposure prophylaxis to prevent hepatitis B infection, especially in individuals exposed to HBV (such as after perinatal exposure, needle stick injuries, or sexual exposure), and in combination with hepatitis B vaccine to prevent reinfection following liver transplantation. HBIG is approved and in current clinical use worldwide.
Pharmacokinetic parameter estimates primarily from healthy adult volunteers after intramuscular administration; in clinical use, parameters may vary depending on individual factors.